Major histocompatibility complex, class II, DR beta 6 (HLA-DRB6)

Major histocompatibility complex, class II, DR beta 6 (HLA-DRB6) is officially designated as a **pseudogene** in humans, meaning it does not encode a functional protein[4][5]. It is one of several beta-chain genes in the HLA-DR region, which normally forms part of the MHC class II cell surface receptor involved in antigen presentation to T cells[1]. However, HLA-DRB6 is **missing exon 1**, which encodes the signal peptide and N-terminal residues required for proper protein targeting and function, and also lacks the canonical promoter necessary for physiological transcription[2][5]. Some low-level, aberrant transcription may occur, but no productive, functional protein is generated[2]. Studies have shown that evolutionary events such as retroviral insertion and exon loss contributed to its pseudogene status[2]. HLA-DRB6 therefore has **no established role in immune function, disease, or as a drug target**[4][5]. It is not a therapeutic target, has no established interaction with known drugs, and does not serve as a biomarker. Key points: - HLA-DRB6 is a pseudogene, not a protein-coding, functional receptor[4][5]. - It does not encode a functional product, lacks essential exons, and has a disrupted promoter[2][4]. - Not considered a **therapeutic target**. - Not directly implicated in disease or drug interactions; does not contribute to classical MHC class II immune responses[2][4]. - All entries for functional activity, biomarkers, drug interactions, and clinical utility are null, as this is not a functional gene.

Other names

HLA-DRB6Major histocompatibility complex, class II, DR beta 6 (pseudogene)